Momelotinib Hits the Mark for Deadly Bone Marrow Cancer Momelotinib Hits the Mark for Deadly Bone Marrow Cancer

The investigational drug has shown benefits in myelofibrosis in a new phase 3 trial with a new sponsor, which plans to apply for FDA approval.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news